Dexmedetomidine for Prevention of Postoperative Delirium After Intracranial Operation for Brain Tumor
Status:
Not yet recruiting
Trial end date:
2021-10-01
Target enrollment:
Participant gender:
Summary
Postoperative delirium is common after major surgery, and is associated with adverse
outcomes. Systematic reviews and meta-analyses of randomized controlled trials have shown
that perioperative administration of dexmedetomidine may decrease the incidence of
postoperative delirium in patients after either cardiac or non-cardiac surgery. However,
neurosurgical patients are often excluded in clinical trials of postoperative delirium.
In this prospective, multicenter, randomized, double-blinded, and placebo-controlled trial
with two parallel arms, ICU admitted adult patients after intracranial operation for brain
tumor will be enrolled. Low-dose dexmedetomidine will be applied during the early
postoperative phase. The investigators aim to evaluate the efficacy and safety of low-dose
dexmedetomidine for prevention of postoperative delirium in this patient population. The
primary hypothesis is that, compared to the placebo group, the prophylactic use of low-dose
dexmedetomidine can decrease the incidence of postoperative delirium without significant
adverse events in patients after intracranial operation for brain tumor.